ISIN:DE000A3H2184

EQS-News: ​​​​​​​Pareto Securities AS publishes buy recommendation for Epigenomics AG share

Retrieved on: 
Sunday, January 22, 2023
Cancer, Clinical trial, ECX, Epigenomics, Research, News, Multiomics, Colorectal cancer, Pareto, OTCQX, Research report, CRC, Centers for Medicare & Medicaid Services, Particle-size distribution, FDA, Epigenomics AG, CMS, Medicare, Pharmaceutical industry

Berlin (Germany), December 23, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Pareto Securities AS has published an updated research report upgrading Epigenomics AG's share and issuing a buy recommendation.

Key Points: 
  • Berlin (Germany), December 23, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Pareto Securities AS has published an updated research report upgrading Epigenomics AG's share and issuing a buy recommendation.
  • Greg Hamilton, CEO of Epigenomics AG: "We are very pleased with the buy recommendation, which we believe reflects the strong test results Epi proColon "Next-Gen" has achieved in the preclinical study.
  • For the upcoming clinical trial, the number of cancer cases in our pre-clinical data exceeds the necessary number to obtain FDA approval.
  • We are very confident that our test will confirm the preclinical performance data in the prospective clinical trial and thus achieve reimbursement by CMS."

EQS-News: Epigenomics Releases Performance Data on Next Generation Test

Retrieved on: 
Sunday, December 18, 2022
Colorectal cancer, Adenoma, Mortality, OTCQX, Epigenomics AG, CRC, DNA methylation, Food, FDA, DNA, CMS, Email, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FIT, AG, News, Medicare, ECX, Disease, Security (finance), Pharmaceutical industry, Epigenomics

Epigenomics’ Next Generation test demonstrates 84% sensitivity in pre-clinical testing.

Key Points: 
  • Epigenomics’ Next Generation test demonstrates 84% sensitivity in pre-clinical testing.
  • Performance exceeds on-market standard of FIT testing for CRC screening.
  • “We are very pleased with the pre-clinical performance of our new multiomics-solution for CRC testing.
  • Epigenomics' lead product is the blood test Epi proColon® for the early detection of colorectal cancer.

EQS-News: Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test

Retrieved on: 
Sunday, December 18, 2022
Colorectal cancer, University, Mortality, OTCQX, Epigenomics AG, CRC, Food, Marketing, FDA, DNA, Cancer, CE marking, Regulation of tobacco by the U.S. Food and Drug Administration, FIT, Liver cancer, AG, News, ECX, Biomarker, Security (finance), Pharmaceutical industry, Epigenomics

Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer.

Key Points: 
  • Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer.
  • Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics develops and markets blood tests for various cancer indications with high unmet medical need.
  • Epigenomics' lead product is the blood test Epi proColon® for the early detection of colorectal cancer.
  • HCCBloodTest, a blood test for the detection of liver cancer, have received the CE Mark for marketing in Europe.

EQS-News: ​​​​​​​Epigenomics AG reports financial results for the first nine months 2022

Retrieved on: 
Friday, November 11, 2022
Epigenomics AG, Institutional review board, CET, Marketing, Federal Executive Boards, Liver cancer, Center, Aktiengesellschaft, Food, Board of directors, Webcast, Colorectal cancer, Technology, Sale, Board, COVID-19, AG, Trial of the century, Regulation of tobacco by the U.S. Food and Drug Administration, Biobank, FSE, DNA, Goal, EBITDA, OTCQX, CE marking, Company, CRC, Cancer, ECX, Clinical trial, Centers for Medicare & Medicaid Services, Research, Medicare, Patient, CEO, Center for Medicare and Medicaid Innovation, News, EDT, AGM, CMS, FDA, Income, Security (finance), Film, Pharmaceutical industry, Petroleum jelly, Cryptocurrency, Online shopping, Epigenomics, EUR

Berlin (Germany) and San Diego, CA (U.S.A.), November 9, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2022.

Key Points: 
  • Berlin (Germany) and San Diego, CA (U.S.A.), November 9, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2022.
  • Sales, general and administrative expenses decreased from EUR 5,809 thousand in the previous year to EUR 5,315 thousand in the first nine months of 2022.
  • The financial report for the first nine months of 2022 can be found on Epigenomics' website at: https://www.epigenomics.com/news-investors/financial-reports/ .
  • Epigenomics AG will host a conference call for analysts and investors today at 4.00 pm (CET) / 10.00 am (EDT).

EQS-News: Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test

Retrieved on: 
Monday, September 19, 2022
ECX, Risk, PMA, FDA, Food, AG, Liquid biopsy, Blood, Biomarker, News, Colorectal cancer, CRC, 970, OTCQX, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Physician, EQS, CEO, Technology, Clinical, DNA, Communication, Epigenomics AG, Security (finance), Pharmaceutical industry, Epigenomics

The prospective, multi-center study titled CRC-DRAW (CRC-Detection Reliable Assessment With Blood) will enroll screening eligible participants 45 years of age and older who are at average risk for colorectal cancer.

Key Points: 
  • The prospective, multi-center study titled CRC-DRAW (CRC-Detection Reliable Assessment With Blood) will enroll screening eligible participants 45 years of age and older who are at average risk for colorectal cancer.
  • Over the course of the trial, it is expected to enroll over 15,000 subjects to achieve the proposed statistical endpoints needed for the study.
  • Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer.
  • Epigenomics' lead product is the blood test Epi proColon for the early detection of colorectal cancer.